Zila Nutraceuticals Establishes Scientific Advisory Board

PHOENIX, Jan 11, 2006 (BUSINESS WIRE) -- Zila, Inc.'s, (ZILA) wholly owned subsidiary, Zila Nutraceuticals, Inc., manufacturer of Ester-C(R) and Ester-E(R), has established a Scientific Advisory Board to provide scientific advice and guidance to the company. Larry Robinson, PhD, Zila's Vice President of Scientific Affairs stated, "We are excited that this panel of internationally recognized nutrition and health experts will be working with us to help direct our nutraceutical research, development and marketing initiatives."

Previously conducted research suggests that both Ester-C(R) and Ester-E(R) may be more proactive in helping to maintain healthy immune and cardiovascular function due to their particular and unique proprietary properties. "We look forward to working with these respected researchers and clinicians as we further our clinical research efforts," said Dr. Robinson. "They will be an important part of our team and offer the opportunity for Zila to effectively supplement the research already available or soon to be published on our line of patented 'Ester' products," he added.

Advisory Board Members are, in alphabetical order:

Vern S. Cherewatenko, MD, MEd, founder of HealthMax Incorporated, a medical wellness company, founder of the 'Cares For America' program that provides medical services for patients who then volunteer time at a charitable organization to pay off their bill, and a founder of the American Association of Patients and Providers, Inc., a non-profit organization to promote changes in healthcare that are wellness-focused and promote patient choice. Dr. Cherewatenko is the author of a number of patient education programs, doctor education programs, has written two books: The Diabetes Cure and The Stress Cure.

Mohsen Meydani, DVM, PhD, Director of Vascular Biology Program and Senior Scientist at Tufts University's Jean Mayer USDA Human Nutrition Research Center on Aging. Dr. Meydani's research focuses on the role of dietary antioxidants, lipids and oxidative stress on molecular mechanisms of immune/endothelial cells interaction in atherogenesis and angiogenesis. Dr. Meydani has published more than 150 scientific original and review articles.

Mark Moyad, MD, MPH. Dr. Moyad occupies an endowed position created and funded entirely by his patients. He is the Phil F. Jenkins Director of Preventive & Alternative Medicine at the University of Michigan Medical Center (Department of Urology). The primary author of over 80 medical articles, Dr. Moyad is the editor-in-chief of the soon to be released medical journal "Seminars in Preventive & Alternative Medicine" by Elsevier. He is an editor or regular reviewer for numerous medical journals including British Journal of Urology, Cancer, European Urology, International Journal of Cancer, Lancet, Journal of Urology, Nutrition and Cancer, Urology and others.

About Ester-C(R)

Ester-C is an advanced form of vitamin C that is pH neutral, providing a form that is easily tolerated by the body. During the patented process of producing Ester-C, the ascorbic acid undergoes changes similar to those that occur in the body, which results in vitamin C metabolites. It is the only vitamin C that contains these metabolites, which help it work differently than regular vitamin C. Ester-C has also been clinically proven to remain active in the immune system for 24 hours.

About Ester-E(R)

Ester-E is an advanced form of vitamin E containing d-alpha tocopheryl phosphates (or "TP" for short). Until recently, scientists were unaware of this important source of vitamin E in the body. Research suggests that the human body may convert other forms of vitamin E into TP in order to protect the vitamin's antioxidant strength until the body is ready to use it. Scientists are now able to replicate this natural form of vitamin E by joining a phosphate molecule to natural vitamin E in a patented process, preserving vitamin E's natural health benefits until the body is ready to use it. Therefore, Ester-E is protected until it is needed, rather than being used up prematurely.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Visit www.Ester-E.com or www.Ester-C.com for more information about the "Ester" line of premium products.

About Zila, Inc.

Zila, Inc., headquartered in Phoenix, is an innovator in preventative healthcare technologies and products, focusing on enhanced body defense and the detection of pre-disease states. Zila has three business units:

-- Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented Zila(R) Tolonium Chloride and OraTest(R) technologies.

-- Zila Pharmaceuticals, marketer of products to promote oral health and prevent oral disease, including ViziLite(R) Plus oral examination kits and Peridex(R) prescription periodontal rinse.

-- Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and Ester-E(R), branded, highly effective forms of Advanced Protection vitamins C and E.

-- For more information about Zila, visit www.zila.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2005.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.